MX2023006020A - Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico. - Google Patents

Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.

Info

Publication number
MX2023006020A
MX2023006020A MX2023006020A MX2023006020A MX2023006020A MX 2023006020 A MX2023006020 A MX 2023006020A MX 2023006020 A MX2023006020 A MX 2023006020A MX 2023006020 A MX2023006020 A MX 2023006020A MX 2023006020 A MX2023006020 A MX 2023006020A
Authority
MX
Mexico
Prior art keywords
combination
abemaciclib
annulene
oxyphenyl
fluoropropyl
Prior art date
Application number
MX2023006020A
Other languages
English (en)
Inventor
Monsif Bouaboula
Zhuyan Guo
Fangxian Sun
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2023006020A publication Critical patent/MX2023006020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente memoria se proporciona una combinación de abemaciclib y de ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoro propil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2 -carboxílico, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que contiene dicha combinación, y los usos terapéuticos de la misma, en particular para el tratamiento del cáncer, incluyendo el cáncer de mama.
MX2023006020A 2020-11-23 2021-11-23 Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico. MX2023006020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20315465 2020-11-23
PCT/EP2021/082583 WO2022106711A1 (en) 2020-11-23 2021-11-23 Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Publications (1)

Publication Number Publication Date
MX2023006020A true MX2023006020A (es) 2023-06-08

Family

ID=73855492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006020A MX2023006020A (es) 2020-11-23 2021-11-23 Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.

Country Status (10)

Country Link
US (1) US20230404971A1 (es)
EP (1) EP4247363A1 (es)
JP (1) JP2023550149A (es)
KR (1) KR20230112626A (es)
CN (1) CN116782895A (es)
AU (1) AU2021382148A1 (es)
CA (1) CA3199466A1 (es)
IL (1) IL303041A (es)
MX (1) MX2023006020A (es)
WO (1) WO2022106711A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107616A1 (es) * 2016-02-15 2018-05-16 Sanofi Sa Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
BR112021010169A2 (pt) * 2018-11-30 2021-08-17 Radius Pharmaceuticals, Inc. elacestrant em combinação com abemaciclib em mulheres com câncer da mama
JP2022531898A (ja) * 2019-05-09 2022-07-12 サノフイ 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸

Also Published As

Publication number Publication date
KR20230112626A (ko) 2023-07-27
CN116782895A (zh) 2023-09-19
US20230404971A1 (en) 2023-12-21
WO2022106711A1 (en) 2022-05-27
EP4247363A1 (en) 2023-09-27
CA3199466A1 (en) 2022-05-27
AU2021382148A9 (en) 2024-06-20
IL303041A (en) 2023-07-01
AU2021382148A1 (en) 2023-07-06
JP2023550149A (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MX2021013711A (es) Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
EP1546136A4 (en) BENZOPYRANE DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES, INCLUDING IMIDAZOLE, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
HK1157337A1 (es)
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
EP2087891A3 (en) Pharmaceutical compositions for treating lymphoma
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
JP2018090566A5 (es)
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
MX2023006020A (es) Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
MX2022010539A (es) Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico.
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
ATE448796T1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
WO2024073328A3 (en) Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer
WO2001074809A1 (fr) Derives d'acylthiophene et leur utilisation en tant que medicaments
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
BG106428A (en) Pharmaceutical compositions for treating psoriasis